Open access
Open access
Powered by Google Translator Translator

Pharmacology/Pharmaceutical Industry

Is shorter always better? The pros and cons of treating Gram-negative bloodstream infections with 7 days of antibiotics.

24 Jun, 2022 | 11:38h | UTC

Is shorter always better? The pros and cons of treating Gram-negative bloodstream infections with 7 days of antibiotics – JAC-Antimicrobial Resistance

 


EULAR/PRES recommendations for vaccination of pediatric patients with autoimmune inflammatory rheumatic diseases.

24 Jun, 2022 | 11:17h | UTC

EULAR/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021 – Annals of Rheumatic Diseases

 


Ivermectin for COVID-19 Cochrane review update: 11 trials and no evidence of benefit shown.

23 Jun, 2022 | 10:38h | UTC

News Release: Ivermectin for COVID-19 review update: 11 trials and no evidence of benefit shown – Liverpool School of Tropical Medicine

Original Article: Ivermectin for preventing and treating COVID‐19 – Cochrane Library

Summary: Ivermectin for preventing and treating COVID-19 – Cochrane Library

 


RCTs: Once daily oral relugolix combination therapy vs. placebo in patients with endometriosis-associated pain.

23 Jun, 2022 | 10:30h | UTC

Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2) – The Lancet

Commentaries:

Relugolix combination therapy for endometriosis pain – The Lancet (free registration required)

Relugolix demonstrates positive phase 3 data as combination therapy for endometriosis pain – Contemporary OB/GYN

 

Commentary on Twitter

 


Metformin and reduced vitamin B12 levels: new advice for monitoring patients at risk.

23 Jun, 2022 | 10:22h | UTC

Metformin and reduced vitamin B12 levels: new advice for monitoring patients at risk – UK Medicines and Healthcare products Regulatory Agency

 


M-A: Intravenous iron vs. oral iron vs. no iron with or without erythropoiesis‐ stimulating agents for cancer patients with anemia.

23 Jun, 2022 | 10:10h | UTC

Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta‐analysis – Cochrane Library

Summary: Which combinations of medicines are best for the prevention and treatment of anaemia in people with cancer? – Cochrane Library

 


USPSTF Statement: The current evidence is insufficient to recommend vitamins for the prevention of cardiovascular disease or cancer.

22 Jun, 2022 | 12:21h | UTC

Vitamin, Mineral, and Multivitamin Supplementation to Prevent Cardiovascular Disease and Cancer: US Preventive Services Task Force Recommendation Statement – JAMA

Evidence Report and Systematic Review: Vitamin and Mineral Supplements for the Primary Prevention of Cardiovascular Disease and Cancer – JAMA

Patient Page: Vitamins and Minerals to Prevent Cardiovascular Disease and Cancer – JAMA

Editorial: Why Too Many Vitamins Feels Just About Right – JAMA Internal Medicine

Author Interview: Why Too Many Vitamins Feels Just About Right – JAMA

Commentary: Vitamins, Supplements Useless for Most People: Expert Panel – HealthDay

 


Review: SARS-CoV-2 infection and COVID-19 vaccination in pregnancy.

22 Jun, 2022 | 12:09h | UTC

SARS-CoV-2 infection and COVID-19 vaccination in pregnancy – Nature Reviews Immunology

 


Cohort Study: Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA.

22 Jun, 2022 | 12:07h | UTC

Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases – The Lancet

Commentaries:

COVID-19 mRNA vaccination and myocarditis or pericarditis – The Lancet

Myocarditis and Pericarditis After the COVID-19 mRNA Vaccination – American College of Cardiology

Related:

SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents – JAMA Cardiology

Myocarditis and pericarditis after COVID-19 vaccination: clinical management guidance for healthcare professionals – UK Health Security Agency

Myocarditis following a third Pfizer vaccination dose in military recruits in Israel.

Myocarditis following COVID-19 BNT162b2 vaccination among adolescents in Hong Kong.

[Preprint] Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy.

Myocarditis after BNT162b2 vaccination in Israeli adolescents.

Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021.

A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

 


Comparing the Pfizer and Moderna Covid vaccines for young children.

22 Jun, 2022 | 12:02h | UTC

Comparing the Pfizer and Moderna Covid vaccines for young children – STAT

Related: FDA advisers OK COVID-19 vaccines for youngest kids – CIDRAP

 


Position Paper: Diagnosis and management of infections caused by multidrug-resistant bacteria.

22 Jun, 2022 | 11:23h | UTC

A position paper for the diagnosis and management of infections caused by multidrug-resistant bacteria: Endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI), and the Italian Society of Microbiology (SIM) – International Journal of Antimicrobial Agents

Related Guideline:

IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections: Version 2.0 – Infectious Diseases Society of America

IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections: Version 1.0 – Infectious Diseases Society of America

 


RCT: Efficacy and safety of varenicline for smoking cessation in patients with type 2 diabetes.

22 Jun, 2022 | 11:16h | UTC

Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Type 2 Diabetes: A Randomized Clinical Trial – JAMA Network Open

Author Interview: Efficacy and Safety of Varenicline in Patients With Type 2 Diabetes – JAMA

 

Commentary on Twitter

 


RCT: Multispecies probiotic for the prevention of antibiotic-associated diarrhea in children.

22 Jun, 2022 | 11:12h | UTC

Multispecies Probiotic for the Prevention of Antibiotic-Associated Diarrhea in Children: A Randomized Clinical Trial – JAMA Pediatrics (free for a limited period)

Commentary: Mixed Results With Probiotic for Kids’ Antibiotic-Related Diarrhea— Randomized trial misses strictly defined endpoint, but researchers point to benefit – MedPage Today (free registration required)

 

Commentary on Twitter

 


Cohort Study: Polypharmacy, potentially inappropriate medications, and drug-drug interactions in vulnerable older adults with advanced cancer initiating cancer treatment.

22 Jun, 2022 | 10:51h | UTC

Polypharmacy, Potentially Inappropriate Medications, and Drug-Drug Interactions in Vulnerable Older Adults With Advanced Cancer Initiating Cancer Treatment – The Oncologist

Commentaries:

Polypharmacy can lead to harmful drug interactions, especially among cancer patients – News Medical

Analysis Underscores Risks of Polypharmacy in Elderly Patients With Cancer – AJMC

 

Commentary on Twitter

Under a https://creativecommons.org/licenses/by/4.0/ license

 


M-A: Opioid versus opioid-free analgesia after surgical discharge.

21 Jun, 2022 | 11:08h | UTC

Opioid versus opioid-free analgesia after surgical discharge: a systematic review and meta-analysis of randomised trials – The Lancet (link to abstract – $ for full-text)

News Release: Taking opioids at home after surgery: More harms than benefits – McGill University Health Center

 


Onconephrology: Update in anticancer drug-related nephrotoxicity.

21 Jun, 2022 | 10:47h | UTC

Onconephrology: Update in Anticancer Drug-Related Nephrotoxicity – Nephron

Related:

Acute Kidney Injury in Critically Ill Patients with Cancer – Clinical Journal of the American Society of Nephrology

Nephrotoxicity of cancer therapeutic drugs: Focusing on novel agents – Kidney Research and Clinical Practice

KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer – Kidney International

 

Commentary from the author on Twitter

 


M-A: Benefits and risks of rapid initiation of antiretroviral therapy in patients with HIV.

21 Jun, 2022 | 10:41h | UTC

Benefits and Risks of Rapid Initiation of Antiretroviral Therapy: A Systematic Review and Meta-Analysis – Frontiers in Pharmacology

 


Cluster RCT: Evaluation of a multicomponent intervention consisting of education and feedback to reduce benzodiazepine prescriptions by general practitioners.

21 Jun, 2022 | 10:29h | UTC

Evaluation of a multicomponent intervention consisting of education and feedback to reduce benzodiazepine prescriptions by general practitioners: The BENZORED hybrid type 1 cluster randomized controlled trial – PLOS One

 


WHO Interim statement on decision-making considerations for the use of variant updated COVID-19 vaccines.

20 Jun, 2022 | 10:42h | UTC

Interim statement on decision-making considerations for the use of variant updated COVID-19 vaccines – World Health Organization

See also: Interim statement on the composition of current COVID-19 vaccines – World Health Organization

 

Commentary on Twitter (thread – click for more)

 


[Preprint] Open-label RCT: Baricitinib noninferior to Tocilizumab in hospitalized patients with severe COVID-19.

20 Jun, 2022 | 10:28h | UTC

Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial – medRxiv

Related:

Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial – The Lancet Respiratory Medicine

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis – medRxiv

WHO recommends two new drugs to treat COVID-19 – World Health Organization

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial – The Lancet Respiratory Medicine

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 – New England Journal of Medicine

 

Commentary on Twitter

 


RCT: Safety and efficacy of Eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures.

20 Jun, 2022 | 01:01h | UTC

Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial – The Lancet Neurology (link to abstract – $ for full-text)

 


Test-negative, case–control study: Effects of previous infection and vaccination on symptomatic omicron infections.

17 Jun, 2022 | 11:44h | UTC

Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections – New England Journal of Medicine

Commentary: Qatar Omicron-wave study shows slow decline of natural immunity, rapid decline of vaccine immunity – Weill Cornell Medicine

Related:

Hybrid immunity: a combination of vaccination and prior infection probably offers the best protection against COVID – The Conversation

Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2 – New England Journal of Medicine

SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity – Environmental Research

Two new studies show vaccination provides additional protection after Covid-19 infection.

 

Commentary on Twitter

 


FDA advisers OK COVID-19 vaccines for youngest kids.

17 Jun, 2022 | 11:43h | UTC

FDA advisers OK COVID-19 vaccines for youngest kids – CIDRAP

See also: FDA advisers endorse 1st COVID-19 shots for kids under 5 – Associated Press

 


Pfizer’s Paxlovid study fails to answer key questions over benefit for broader populations.

15 Jun, 2022 | 11:22h | UTC

Pfizer’s Paxlovid study fails to answer key questions over benefit for broader populations – STAT

 


RCT: Effectiveness and safety of lotion, cream, gel, and ointment emollients for childhood eczema.

15 Jun, 2022 | 11:20h | UTC

Effectiveness and safety of lotion, cream, gel, and ointment emollients for childhood eczema: a pragmatic, randomised, phase 4, superiority trial – The Lancet Child & Adolescent Health

News Release: The right moisturiser for children with eczema is the one that they like to use, study finds – University of Nottingham

Commentary: Lotion, Cream, Gel, and Ointment Similarly Effective for Childhood Eczema – HealthDay

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.